FIELD: biotechnology.
SUBSTANCE: invention relates to fusion proteins PD1-4-1BBL, and can be used in medicine for treating cancer, cells of which express PD-L1. Constructing a fusion protein PD1-4-1BBL in the form of a homotrimer, containing at its N-end the amino acid sequence of programmed death 1 (PD1), and at its C-end amino acid sequence of ligand 4-1BB (4-1BBL), connected by means of linker from one glycine.
EFFECT: invention enables to obtain a fusion protein which is capable of binding PD-L1 and 4-1BB, activating said 4-1BB signaling pathway in a cell, expressing said 4-1BB and co-stimulation of immune cells expressing said 4-1BB.
11 cl, 1 tbl, 12 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
| EMBODIMENTS OF SIRP-ALPHA-4-1BBL FUSION PROTEIN AND METHODS OF USE THEREOF | 2019 |
|
RU2815515C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
| MESOTHELINIC CAR RECEPTORS AND USE THEREOF | 2020 |
|
RU2822193C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| VECTOR, CO-EXPRESSING MOLECULES FOR VACCINATION AND COSTIMULATORY MOLECULES | 2016 |
|
RU2714157C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
